We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 25, 2021

Age-Based Outcomes in Patients With mRCC Treated With First-Line Targeted Therapy or Checkpoint Immunotherapy

Journal of Geriatric Oncology


Additional Info

Journal of Geriatric Oncology
Outcomes Based on Age in Patients With Metastatic Renal Cell Carcinoma Treated With First Line Targeted Therapy or Checkpoint Immunotherapy: Older Patients More Prone to Toxicity
J Geriatr Oncol 2020 Dec 31;[EPub Ahead of Print], CK Hermansen, F Donskov

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading